Comparison of the Feasibility and Safety of First- versus Second-Generation AMPLATZER™ Occluders for Left Atrial Appendage Closure

Table 1

Patient characteristics.

	ACP; (%) or value; ()	Amulet; (%) or value; ()
Age (years)			0.36
Age ≥ 75 (years)	56 (57)	53 (55)	0.85
Male	63 (64)	57 (59)	0.43
Body mass index (kg/m^2)			0.43
CHA2DS2VASC score			0.90
HASBLED score			0.44
Atrial fibrillation
Paroxysmal/persistent	41 (41)	53 (55)	0.06
Permanent AF	58 (59)	44 (45)	0.06
Clinical features
Coronary artery disease	43 (43)	46 (47)	0.58
Myocardial infarction	19 (19)	16 (16)	0.62
PCI	24 (24)	29 (30)	0.38
CABG	13 (13)	9 (9)	0.40
CMP	12 (12)	13 (13)	0.79
Arterial hypertension	94 (95)	91 (94)	0.73
Diabetes mellitus	26 (26)	34 (35)	0.18
Hyperlipidemia	45 (45)	47 (48)	0.68
Creatinine			0.68
Quick			0.67
INR			0.63
PTT (sec)			0.44
Nicotine	31 (31)	24 (25)	0.31
Medication before LAA occlusion
Clopidogrel	23 (23)	14 (14)	0.12
Vitamin K antagonist	20 (20)	34 (35)	0.02
New oral anticoagulant drug	19 (19)	29 (30)	0.08
Low molecular weight heparin	47 (47)	18 (19)	<0.001
Beta-blocker	84 (85)	72 (74)	0.06
Statin therapy	43 (43)	42 (43)	0.99
Diuretics	63 (64)	65 (67)	0.62
ACE inhibitor	42 (42)	33 (34)	0.23
Risk factors for bleeding
Previous stroke/TIA	31 (31)	35 (36)	0.48
Prior major bleeding	47 (48)	50 (52)	0.57
Renal disease	31 (31)	33 (34)	0.69
Liver disease	5 (5)	6 (6)	0.73
Labile INR	5 (5)	0 (0)	0.03
Age > 65	91 (92)	84 (87)	0.23